C. Mei

发表

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Chao Hu, Weilai Xu, 2018, Journal of Cancer Research and Clinical Oncology.

The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts

Yingwan Luo, Yanling Ren, Xinping Zhou, 2018, Leukemia & lymphoma.

Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

Jie Jin, Yue-min Kuang, Yanling Ren, 2020, Hematological oncology.

Clinical and biological characteristics of acute myeloid leukemia with 20–29% blasts: a retrospective single-center study

Jie Jin, P. Lin, Yingwan Luo, 2018, Leukemia & lymphoma.

Analysis of clinical and molecular features of MDS patients with complex karyotype in China.

Jie Jin, P. Lin, Yingwan Luo, 2019, Blood cells, molecules & diseases.

Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method

Y. Lou, C. Mei, H. Tong, 2022, Molecules.

TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2020, Asia-Pacific journal of clinical oncology.

Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2020, American journal of cancer research.

A new complex translocation t(9;17;15)(q31;q21;q22) in acute promyelocytic leukemia

Jie Jin, Jinlan Pan, Jun Zhang, 2009, Leukemia & lymphoma.

Clinical Characteristics and Outcomes of Tuberculosis Infection in Adult Patients with MDS

Yingwan Luo, Shuanghong Zhu, Haiyang Yang, 2020 .

Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study

Jie Jin, Xinping Zhou, C. Mei, 2021, Leukemia & lymphoma.

Tigecycline and homoharringtonine synergistically target myeloid leukemia cells by inhibiting mitochondrial translation through mTOR/4EBP1 pathway

Jian Huang, Haiyang Yang, Hua Zhang, 2020 .

Intestinal ulcers in a patient with myelodysplastic syndrome: a case report

Chaohui Yu, Lan Li, Zhe Shen, 2021, BMC Gastroenterology.

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex

Xiaozhen Liu, P. Lin, Yingwan Luo, 2022, British Journal of Cancer.

Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target

J. Vera, Jie Jin, Z. Ren, 2014, Journal of Translational Medicine.

Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2022, Journal of Cancer Research and Clinical Oncology.

Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes

Jie Jin, Yingwan Luo, Shuanghong Zhu, 2019, Cancer science.

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Jie Jin, Z. Zhuang, D. Maggio, 2017, Scientific Reports.

Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting

Jie Jin, Fangjing Shi, P. Lin, 2019, Leukemia & lymphoma.

Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.

Jie Jin, Yingwan Luo, Chao Hu, 2019, Blood cells, molecules & diseases.

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

Jie Jin, W. Qian, P. Lin, 2017, Journal of Cancer Research and Clinical Oncology.

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Jie Jin, Xiaomei Yan, M. Azam, 2018, Haematologica.

Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases

Jian Huang, Jie Jin, W. Qian, 2016, Frontiers of Medicine.

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study.

Jianping Shen, Chao Hu, Xinping Zhou, 2023, The Journal of infection.

Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid

Jie Jin, C. Mei, H. Tong, 2011, Annals of Hematology.

Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study

Jie Jin, P. Lin, Yingwan Luo, 2021, Cancer medicine.

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study

Yingwan Luo, Haiyang Yang, Xinping Zhou, 2022, Hematological oncology.

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Jie Jin, Z. Zhuang, P. Lin, 2018, Journal of Cancer Research and Clinical Oncology.

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Jian Huang, Jie Jin, Chao Hu, 2016, Leukemia & lymphoma.

RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells

Yingwan Luo, Shuanghong Zhu, Xinping Zhou, 2024, Science advances.

Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome

Yingwan Luo, Xinping Zhou, C. Mei, 2022, Hematological oncology.